12:22 PM EST - DiagnoCure, Inc. : and Signal Genetics, a privately-held predictive genetic testing company focusing on oncology, announced a collaboration arrangement valued at $13.3 million U.S. over the first five years. This collaboration aims to maximize the commercialization of Previstage(TM) GCC Colorectal Cancer Staging Test, and further develop novel genomic cancer tests in the field of Personalized Medicine. DiagnoCure, Inc.
shares T.CUR are trading up $0.08 at $0.87.
